Wet Age-Related Macular Degeneration

Description

With the introduction of Roche's Vabysmo challenging Bayer/Regeneron's Eylea, the dynamics of first-line choices are shifting. Meanwhile, off-label Avastin remains a cost-effective option, though its usage may wane with new advancements. As we look to the future, the focus sharpens on longer treatment intervals, improved visual acuity, and less invasive options, highlighting the potential of gene therapies, tyrosine kinase inhibitors, and innovative drugs like D 4517.2 and Axpaxli. This pivotal moment in wAMD treatment calls for a strategic pivot towards addressing unmet needs and embracing novel therapeutic pathways.

Executive summary (14)

Treatment algorithm

Research objectives (2)

VEGF inhibitors (71)

Marketed therapies (71)
- Vabysmo (faricimab; Roche) (21)
- Eylea (aflibercept; Bayer/Regeneron Pharmaceuticals) (21)
- Lucentis (ranibizumab; Roche/Novartis) (18)
- Beovu (brolucizumab; Novartis) (11)

VEGF inhibitors (70)

Marketed therapies used off label (13)
- Avastin (bevacizumab; Roche) (13)
Pipeline therapies (57)
- Sozinibercept (OPT-302; Opthea) (16)
- D-4517.2 (Asvattha Therapeutics) (17)
- Lytenava (bevacizumab ophthalmic; Outlook Therapeutics) (14)
- Yesafili (aflibercept biosimilar; Momenta Pharmaceuticals/Viatris/Biocon) (10)

Tyrosine kinase inhibitors (24)

Pipeline therapies (24)
- Axpaxli (axitinib intravitreal implant/OTX-TKI; Ocular Therapeutix) (12)
- Vorolanib (Equinox Sciences/EyePoint Pharmaceuticals) (12)

Gene therapy (32)

Pipeline therapies (32)
- ABBV-RGX-314 (REGENXBIO/AbbVie) (22)
- Ixoberogene soroparvovec (Ixo-vec; Adverum Biotechnologies) (10)

Future treatment paradigm (15)

Key insights summary (15)
- Pharma companies developing wAMD therapies should focus on treatment duration, ease of administration, safety and new therapeutic pathways (3)